(Total Views: 561)
Posted On: 02/07/2021 4:27:53 PM
Post# of 72446
2/5/2021 FDA limits convalescent antibody treatment after review of data shows disappointing results in very ill patients and patients with adequate antibodies.
"The revision states that only high-titer COVID-19 convalescent plasma can be used and only in hospitalized patients who are early in the disease course and those with impaired humoral immunity who cannot produce an adequate antibody response.
The revisions stem from new clinical trial data analyzed or reported since the original EUA was issued in August 2020. The original EUA did not have these restrictions."
https://www.medscape.com/viewarticle/945396
If Brilacidin proves to be widely effective it will have limited competition.
GLTA,
Farrell
"The revision states that only high-titer COVID-19 convalescent plasma can be used and only in hospitalized patients who are early in the disease course and those with impaired humoral immunity who cannot produce an adequate antibody response.
The revisions stem from new clinical trial data analyzed or reported since the original EUA was issued in August 2020. The original EUA did not have these restrictions."
https://www.medscape.com/viewarticle/945396
If Brilacidin proves to be widely effective it will have limited competition.
GLTA,
Farrell
(6)
(0)
